Cyclacel Pharmaceuticals Inc. Stock
For the coming years our community has positive and negative things to say abot the Cyclacel Pharmaceuticals Inc. stock. Criterium "EBIT Margin" gathered the most positive votes but regarding "Expected Cash Flow" there were negative voices in the community.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 3.660% | 8.974% | 18.056% | -40.351% | -8.602% | -5.028% | -81.027% |
| Vaxart Inc. | -0.710% | -0.639% | -0.356% | -49.821% | -58.457% | -71.193% | -95.333% |
| Achieve Life Sciences Inc. | -2.030% | -2.889% | -4.332% | -2.152% | 8.415% | 59.975% | -38.160% |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat